Targeting the NKG2A immune pathway to treat alopecia areata
Targeting the NKG2A Pathway in Alopecia Areata
This project will try blocking the NKG2A immune signal to reduce the immune attack on hair follicles and help people with alopecia areata regrow hair.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11294331 on NIH RePORTER |
What this research studies
Researchers found a specific type of immune cell (CD8+ T cells) that carries both activating and inhibitory signals and may drive hair loss in alopecia areata. They will study patient immune cells using single-cell sequencing, test how the NKG2A pathway affects those cells, and use lab and mouse models to see whether changing NKG2A signaling calms the immune response. The team aims to develop or repurpose antibodies or other agents that modify NKG2A activity and examine effects on inflammation around hair follicles. Results could guide future treatments that more precisely target the immune attack causing hair loss.
Who could benefit from this research
Good fit: Ideal candidates would be people with active alopecia areata, particularly those with recent or ongoing hair loss and autoimmune-driven forms of the condition.
Not a fit: People whose hair loss is from scarring alopecia, non-autoimmune causes, or irreversible follicle destruction are unlikely to benefit from this approach.
Why it matters
Potential benefit: If successful, this work could reduce immune-driven hair loss and lead to targeted therapies that promote hair regrowth for people with alopecia areata.
How similar studies have performed: Related immune-targeting approaches such as JAK inhibitors have helped some patients with alopecia areata, but directly targeting NKG2A is a newer and less-tested strategy in humans.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Christiano, Angela M — Columbia University Health Sciences
- Study coordinator: Christiano, Angela M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.